DrugPatentWatch Database Preview
UBRELVY Drug Profile
» See Plans and Pricing
Which patents cover Ubrelvy, and when can generic versions of Ubrelvy launch?
Ubrelvy is a drug marketed by Allergan and is included in one NDA. There are five patents protecting this drug.
This drug has eighty-six patent family members in forty countries.
The generic ingredient in UBRELVY is ubrogepant. One supplier is listed for this compound. Additional details are available on the ubrogepant profile page.
DrugPatentWatch® Generic Entry Outlook for Ubrelvy
Ubrelvy will be eligible for patent challenges on December 23, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 30, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for UBRELVY
| International Patents: | 86 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 13 |
| Clinical Trials: | 1 |
| Patent Applications: | 31 |
| Drug Prices: | Drug price information for UBRELVY |
| What excipients (inactive ingredients) are in UBRELVY? | UBRELVY excipients list |
| DailyMed Link: | UBRELVY at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for UBRELVY
Generic Entry Date for UBRELVY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for UBRELVY
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Allergan | Phase 1 |
US Patents and Regulatory Information for UBRELVY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Allergan | UBRELVY | ubrogepant | TABLET;ORAL | 211765-002 | Dec 23, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Allergan | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Allergan | UBRELVY | ubrogepant | TABLET;ORAL | 211765-002 | Dec 23, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for UBRELVY
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | 201520214 | Start Trial |
| Spain | 2604827 | Start Trial |
| European Patent Office | 3102564 | Start Trial |
| Japan | 2017505306 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
